Article
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology - 1 Mar 2017
Shimizu Toshio, Yonesaka Kimio, Hayashi Hidetoshi, Iwasa Tsutomu, Haratani Koji, Yamada Hironori, Ohwada Shoichi, Kamiyama Emi, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) in prior chemotherapy treated Japanese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.